Face validity expressed as the prevalence of remission (%) in recent trials of patients with rheumatoid arthritis*
| Candidate remission definition | DMARD monotherapy (n = 380) | Biologic monotherapy (n = 520) | Combination therapy (n = 330) | Total (n = 1230) |
|---|---|---|---|---|
| TJC, SJC, CRP, PtGA ≤1 | 9 | 7 | 22 | 12 |
| TJC, SJC, CRP, PtGA, pain ≤1 | 8 | 6 | 20 | 12 |
| TJC, SJC, CRP, PhGA, PtGA ≤1 | 8 | 7 | 20 | 10 |
| TJC, SJC, CRP, PhGA, pain ≤1 | 8 | 6 | 20 | 10 |
| TJC, SJC, CRP, PhGA, PtGA, pain ≤1 | 7 | 6 | 18 | 9 |
| DAS28 <2.6 | 19 | 17 | 35 | 21 |
| DAS28 <2.0 | 5 | 8 | 24 | 10 |
| SDAI ≤3.3 | 10 | 8 | 26 | 14 |
↵* From pooled data from refs 37 40, and 41. CRP is in mg/dl.
DAS28 = 28-joint Disease Activity Score; SDAI = Simplified Disease Activity Index (see table 1 for other definitions).